Reversible cardiotoxicity with tyrosine kinase inhibitors.
Francis
Jawad
J
Department of Medicine, State University of New York at Buffalo, Buffalo, NY 14214, USA.
Ahluwalia
Manmeet S
MS
Wetzler
Meir
M
Wang
Eunice
E
Paplham
Pamela
P
Smiley
Shannon
S
McCarthy
Philip L
PL
Cohen
I Larry
IL
Spangenthal
Edward
E
Battiwalla
Minoo
M
D000328:Adult; D001549:Benzamides; D054715:Cardiotoxins / Q000009:adverse effects*; D016543:Central Nervous System Neoplasms / Q000188:drug therapy / Q000556:secondary; D000069439:Dasatinib; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000009:adverse effects; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011743:Pyrimidines / Q000009:adverse effects; D013844:Thiazoles / Q000009:adverse effects; D018487:Ventricular Dysfunction, Left / Q000139:chemically induced*
D001549:Benzamides; D054715:Cardiotoxins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib